A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
DOI:
https://doi.org/10.2340/00015555726567Abstract
A new tablet of micronized 5-methoxypsoralen (5-MOP) and a commonly used tablet in therapy (Psoraderm 5) were compared in 12 healthy subjects. Each subject ingested 1.2 mg/kg body weight of each formulation on different days. Bioavailability and phototoxicity of 5-MOP were compared. The results showed that serum and suction blister concentrations were significantly higher and occurred earlier after the oral intake of the micronized preparation. A series of graduated UVA doses were administered, one dose each time the concentration serum peaked, in order to determine the minimum phototoxic dose for each formulation. The micronized preparation induced greater photosensitivity than the unmicronized one. The micronized 5-MOP tablet may thus allow lower doses of UVA to achieve therapeutic results in photochemotherapy and a shortened waiting period following ingestion of drug.Downloads
Download data is not yet available.
Downloads
Published
1992-01-01
How to Cite
Treffel, P., Makki, S., Humbert, P., Khaldoun, H., & Agache, P. (1992). A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement. Acta Dermato-Venereologica, 72(1), 65–67. https://doi.org/10.2340/00015555726567
Issue
Section
Articles
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
